68Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients

Background Response prediction is necessary for renal cell carcinoma (RCC) tumors. We aim to evaluate parameters derived from 68  Ga-PSMA-11 PET/CT images for prediction of pathological VEGFR-2/PDGFR-β expression of primary RCC tumors. Methods Forty-eight RCC patients were retrospectively enrolled w...

Full description

Saved in:
Bibliographic Details
Published in:Molecular imaging and biology 2022-10, Vol.24 (5), p.759-768
Main Authors: Gao, Jie, Meng, Longxiyu, Xu, Qinfeng, Zhao, Xiaozhi, Deng, Yongming, Fu, Yao, Guo, Suhan, He, Kuiqiang, Shi, Jiong, Wang, Feng, Zhang, Shiwei, Guo, Hongqian
Format: Article
Language:English
Subjects:
Chi-square test
Computed tomography
Continuity (mathematics)
Imaging
Immunohistochemistry
Kidney cancer
Medical imaging
Medicine
Medicine & Public Health
Parameters
Patients
Positron emission
Radiology
Regression analysis
Renal cell carcinoma
Research Article
Subgroups
Tumors
Vascular endothelial growth factor receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Response prediction is necessary for renal cell carcinoma (RCC) tumors. We aim to evaluate parameters derived from 68  Ga-PSMA-11 PET/CT images for prediction of pathological VEGFR-2/PDGFR-β expression of primary RCC tumors. Methods Forty-eight RCC patients were retrospectively enrolled with preoperative 68  Ga-PSMA-11 PET/CT scan and surgical specimen. Radiological parameters including tumor diameter, mean CT value, and maximal standard uptake value (SUV max ) were derived from PET/CT images and pathological VEGFR-2/PDGFR-β/PSMA expression were identified with immunohistochemistry. Mann–Whitney U test was performed for continuous variables and the chi-square test for categorical variables. ROC was used for determining the effectiveness of preoperative parameters in differentiating VEGFR-2/PDGFR-β expression. Univariate and multivariate logistic regression analyses were performed for significant parameters to predict VEGFR-2 & PDGFR-β co-expression. Results Of the 48 tumors, 25 (52.1%) harbored positive VEGFR-2 expression, 28 (58.3%) harbored positive PDGFR-β expression, and 24 (50%) were both VEGFR-2 positive and PDGFR-β positive. SUV max significantly differed by subgroups of VEGFR-2/PDGFR-β expression (both P  
ISSN:1536-1632
1860-2002
DOI:10.1007/s11307-022-01725-1